%0 Journal Article
%T Treatment outcome and prognostic factor analysis in transplant-eligible Chinese myeloma patients receiving bortezomib-based induction regimens including the staged approach, PAD or VTD
%A Chor Sang Chim
%A Albert Kwok Wai Lie
%A Eric Yuk Tat Chan
%A Herman Sung Yu Liu
%A Ching Wa Lau
%A Sze Fai Yip
%A Joycelyn Sim
%A Thomas Shek-Kong Wan
%A Edmond Shiu-Kwan Ma
%A Raymond Liang
%A Eric Tse
%A Yok-Lam Kwong
%J Journal of Hematology & Oncology
%D 2012
%I BioMed Central
%R 10.1186/1756-8722-5-28
%X Ninety-one transplant-eligible Chinese patients received three induction regimens prior to ASCT [staged approach (N£¿=£¿25), PAD (N£¿=£¿31), VTD (N£¿=£¿35)]. and received thalidomide maintenance for 2£¿years post-ASCT.43 (47.3%) patients had International Staging System (ISS) III disease. By an intention-to-treat analysis, the overall CR/nCR rate were 37.4% post-induction, and 62.6% post-ASCT. Five-year overall (OS) and event-free (EFS) survivals were 66% and 45.1%. There was no difference of the post-induction CR/nCR rate, EFS or OS between patients induced by these three regimens. Moreover, ISS III disease did not affect CR/nCR rates. Multivariate analysis showed that ISS and post-ASCT CR/nCR impacted OS while ISS and post-induction CR/nCR impacted EFS.These three induction regimens produced comparable and favorable outcomes in myeloma. The unfavorable outcome of ISS stage III persisted despite upfront/early use of bortezomib. CR/nCR predicted favorable survivals.
%K Myeloma
%K Staged approach
%K PAD
%K VTD
%K Prognostic factors
%K Deep vein thrombosis
%U http://www.jhoonline.org/content/5/1/28/abstract